PPARG and diabetic kidney disease: Moreover, thiazolidinediones are associated with the attenuation of DKD in patients with T2DM (44, 45); the activation of PPARγ slows the progression of DKD, and several mechanisms, both systemic and renal, have been implicated in the renoprotective effects of PPARγ (46).